|drug4032||Tocilizumab Injection Wiki||0.71|
|D002925||Ciliary Motility Disorders NIH||1.00|
There is one clinical trial.
The COVID-PCD is a participatory research project that aims to study how COVID-19 affects people with primary ciliary dyskinesia (PCD). The study is advertised through patient support groups and participants register online and answer a baseline questionnaire with details on PCD diagnosis, habitual symptoms, and COVID-19 episodes occurring before study entry. A short weekly follow-up questionnaire includes questions on incident SARS-CoV-2 infections, current symptoms, contact behaviour, and physical activity. The study is hosted at the University of Bern and recruitment started on May 30th, 2020.
Description: Number of people with PCD who report an infection with SARS-CoV-2Measure: SARS-CoV-2 Time: 6 months
Description: Number of people with PCD who report an infection with SARS-CoV-2 and report symptomsMeasure: COVID-19 Time: 6 months
Description: Number of people with PCD who report a hospital stay due to COVID-19Measure: COVID-19 hospitalisation Time: 6 months
Description: Number of people with PCD who report a hospital stay due to COVID-19 and treatment in intensive careMeasure: COVID-19 intensive care Time: 6 months
Description: Number of people with PCD who reported an infection with SARS-CoV-2 and diedMeasure: COVID-19 fatal outcome Time: 6 months
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports